Testosterone Cypionate/Anastrozole Oil (Drug Depot) – Sterility Concern (2022)
Class II: A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Class II recall indicates potential for temporary health effects.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
TESTOSTERONE CYPIONATE/ANASTROZOLE *GS* OIL 200MG/1MG/ML Injectable, Packaged in a multi dose 10ML vial, as a) 4 ML Formula ID 115387; b) (RM) 10 ML Formula ID 115125; APS Pharmacy
Brand
Drug Depot, Inc., dba APS Pharmacy
Lot Codes / Batch Numbers
Lots: a) 745383 BUD: 6/20/2022, 759295 BUD: 8/30/2022, b) 745749 BUD: 6/21/2022, 746272 BUD: 6/27/2022
Products Sold
Lots: a) 745383 BUD: 6/20/2022; 759295 BUD: 8/30/2022; b) 745749 BUD: 6/21/2022; 746272 BUD: 6/27/2022
Drug Depot, Inc., dba APS Pharmacy is recalling TESTOSTERONE CYPIONATE/ANASTROZOLE *GS* OIL 200MG/1MG/ML Injectable, Packaged in a multi dose 10ML due to Lack of sterility assurance.. This is a Class I recall, indicating a high risk of serious health consequences. Based on FDA drug enforcement report.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Lack of sterility assurance.
Recommended Action
Per FDA guidance
Consumers should stop using the product and contact the recalling firm, their healthcare provider, or return it to the place of purchase.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 7, 2026